Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | FDPS | P14324 | 5/20 | 0.43 |
| ▸ | LAP3 | P28838 | 1/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL9154089 | 1.00 | KDM4E (0.53) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Phosphoric Acid SCHEMBL7566197 | 1.00 | KDM4E (0.53) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL2514522 | 0.96 | — | — | |
| Phosphoric Acid SCHEMBL547410 | 0.96 | KDM4E (0.57) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL912064 | 0.96 | — | — | |
| Phosphoric Acid SCHEMBL9646964 | 0.92 | KDM4E (0.53) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Water SCHEMBL28059026 | 0.92 | — | — | |
| Phosphoric Acid SCHEMBL8025696 | 0.92 | KDM4E (0.53) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL27766663 | 0.92 | KDM4E (0.61) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL35435 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374492-A1 | A SUNSCREEN COMPOSITION COMPRISING AVOBENZONE AND A METHOD FOR PHOTOSTABILIZATION | ISP INVESTMENTS LLC (US) | 2024-11-14 | — | — | US | claimed |
| US-20200306161-A1 | THICKENER SYSTEMS FOR ORAL CARE COMPOSITIONS AND A METHOD FOR PREPARING THE SAME | ISP INVESTMENTS LLC (US) | 2020-10-01 | — | — | US | claimed |
| US-3983227-A | TECHNETIUM | THE PROCTER & GAMBLE COMPANY (US) | 1976-09-28 | — | — | US | claimed |
| US-3934002-A | BIS-GUANIDE | THE PROCTER & GAMBLE COMPANY (US) | 1976-01-20 | — | — | US | claimed |
| US-20250381253-A1 | MUTANASES AND ORAL CARE COMPOSITIONS COMPRISING SAME | NOVOZYMES A/S (DK) | 2025-12-18 | — | — | US | disclosed |
| US-20240374492-A1 | A SUNSCREEN COMPOSITION COMPRISING AVOBENZONE AND A METHOD FOR PHOTOSTABILIZATION | ISP INVESTMENTS LLC (US) | 2024-11-14 | — | — | US | disclosed |
| US-11910724-B2 | Thickener systems for oral care compositions and a method for preparing the same | ISP INVESTMENTS LLC (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230332124-A1 | ORAL CARE COMPOSITION COMPRISING A FRUCTANASE | NOVOZYMES A/S (DK) | 2023-10-19 | — | — | US | disclosed |
| US-20230037975-A1 | USE OF CANNABINOID COMPOUNDS IN ORAL CARE COMPOSITIONS TO INHIBIT THE GROWTH OF P. GINGIVALIS | DEMETRIX, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220347071-A1 | USE OF CANNABINOIDS IN THE TREATMENT OF ORAL INFLAMMATION AND PERIODONTAL DISEASE | DEMETRIX, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20220304911-A1 | ORAL CARE PRODUCT WITH CANNABINOID COMPOUNDS | DEMETRIX, INC. | 2022-09-29 | — | — | US | disclosed |
| EP-2760417-B1 | ORAL CARE COMPOSITIONS | RUBICON RES PRIVATE LIMITED (IN) | 2020-11-11 | — | — | EP | disclosed |
| US-4216212-A | Pyrazolidine anti-inflammatory composition and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 1980-08-05 | — | — | US | disclosed |
| US-4067971-A | ORGANOPHOSPHONATE COMPOUNDS, TREATMENT OF HYPOXIA, ISCHEMIC TISSUE DISEASES | THE PROCTER & GAMBLE COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
| US-4051234-A | BIS-GUANIDINE COMPOUND, ETHYLENEDIAMINEDIACETIC ACID OR SALT AS CHELATOR | THE PROCTER & GAMBLE COMPANY (US) | 1977-09-27 | — | — | US | disclosed |
| US-4025616-A | Oral compositions for plaque, caries and calculus retardation with reduced staining tendencies | THE PROCTER & GAMBLE COMPANY (US) | 1977-05-24 | — | — | US | disclosed |
| US-3983227-A | TECHNETIUM | THE PROCTER & GAMBLE COMPANY (US) | 1976-09-28 | — | — | US | disclosed |
| US-3965254-A | Compositions for the treatment of calcific tumors | THE PROCTER & GAMBLE COMPANY (US) | 1976-06-22 | — | — | US | disclosed |
| US-3937807-A | BISBIGUANIDE COMPOUND | THE PROCTER & GAMBLE COMPANY (US) | 1976-02-10 | — | — | US | disclosed |
| US-3934002-A | BIS-GUANIDE | THE PROCTER & GAMBLE COMPANY (US) | 1976-01-20 | — | — | US | disclosed |